Related references
Note: Only part of the references are listed.Comparison of 2-Dose and 3-Dose 9-Valent Human Papillomavirus Vaccine Schedules in the United States: A Cost-effectiveness Analysis
Jean-Francois Laprise et al.
JOURNAL OF INFECTIOUS DISEASES (2016)
Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study
Rengaswamy Sankaranarayanan et al.
LANCET ONCOLOGY (2016)
Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysis
Laia Bruni et al.
LANCET GLOBAL HEALTH (2016)
The Case for Conducting a Randomized Clinical Trial to Assess the Efficacy of a Single Dose of Prophylactic HPV Vaccines Among Adolescents
Aimee R. Kreimer et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA trials
Aimee R. Kreimer et al.
LANCET ONCOLOGY (2015)
Rationale and design of a long term follow-up study of women who did and did not receive HPV 16/18 vaccination in Guanacaste, Costa Rica
Paula Gonzalez et al.
VACCINE (2015)
The Case for Conducting a Randomized Clinical Trial to Assess the Efficacy of a Single Dose of Prophylactic HPV Vaccines Among Adolescents
Aimee R. Kreimer et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
Raising Expectations For Subunit Vaccine
John T. Schiller et al.
JOURNAL OF INFECTIOUS DISEASES (2015)
Durable Antibody Responses Following One Dose of the Bivalent Human Papillomavirus L1 Virus-Like Particle Vaccine in the Costa Rica Vaccine Trial
Mahboobeh Safaeian et al.
CANCER PREVENTION RESEARCH (2013)
Immunogenicity of 2 Doses of HPV Vaccine in Younger Adolescents vs 3 Doses in Young Women A Randomized Clinical Trial
Simon R. M. Dobson et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2013)
Cross-protective vaccine efficacy of the bivalent HPV vaccine against HPV31 is associated with humoral immune responses Results from the Costa Rica vaccine trial
Mahboobeh Safaeian et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2013)
Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule Results from a randomized study
Barbara Romanowski et al.
HUMAN VACCINES (2011)
Proof-of-Principle Evaluation of the Efficacy of Fewer Than Three Doses of a Bivalent HPV16/18 Vaccine
Aimee R. Kreimer et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2011)
Mechanisms that determine plasma cell lifespan and the duration of humoral immunity
Ian J. Amanna et al.
IMMUNOLOGICAL REVIEWS (2010)
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Jacques Ferlay et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
A review of human carcinogens-Part B: biological agents
Veronique Bouvard et al.
LANCET ONCOLOGY (2009)
Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccine
Francis J. Dessy et al.
HUMAN VACCINES (2008)
Rationale and design of a community-based double-blind randomized clinical trial of an HPV 16 and 18 vaccine in Guanacaste, Costa Rica
Rolando Herrero et al.
VACCINE (2008)
Highly effective detection of human papillomavirus 16 and 18 DNA by a testing algorithm combining broad-spectrum and type-specific PCR
Leen-Jan van Doorn et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2006)
Share Paper
